Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Announces Bassil Dahiyat As Its New Chief Scientific Officer
Dahiyat launched Xencor’s biotherapeutic programs and protein design platform
View HTML
Toggle Summary Xencor Announces Harry Stylli As Its New Chief Executive Officer
Stylli brings record of success in drug development and technology commercialization
View HTML
Toggle Summary Xencor Granted Patent on Optimized Pharmaceutical Protein
US Patent Issued for Novel G-CSF with Improved Pharmaceutical Properties Created by Protein Design Automation Technology
View HTML
Toggle Summary Xencor Designs Novel TNF Alpha Inhibitors To Treat Inflammatory Disease
Xencor’s Protein Design Automation Technology Creates New Modality for Blocking TNF Alpha and Related Proteins
View HTML
Toggle Summary Chromos and Xencor announce agreement for use of the ACE System to produce biologics.
Chromos and Xencor announce agreement for use of the ACE System to produce biologics. Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research
View HTML
Toggle Summary Bassil Dahiyat Named One of the World’s Top Young Innovators
Bassil Dahiyat Named One of the World’s Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Dahiyat To Be Honored September 24-25 at The Emerging Technologies Conference at MIT
View HTML
Toggle Summary Xencor Receives Advanced Technology Program Grant For Safer Protein Therapeutics
(BW Healthwire)–October 09, 2002—Grant to Support the Rational Design of Non-immunogenic Proteins
View HTML
Toggle Summary Xencor Reaches Research Milestone
Xencor Reaches Research Milestone (BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created
View HTML
Toggle Summary Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier
Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company
View HTML
Toggle Summary Xencor Optimizes Key Pharmaceutical Proteins
(BW Healthwire)–May 29, 2002—Xencor’s Protein Design Technology Provides Superior Control and Flexibility in Biotherapeutic Creation
View HTML